

# Spotlight on the national PH service

## Key findings

The statistics here are taken from the 13th National Audit of Pulmonary Hypertension, using data from 2021-22. They represent the evaluation of standards at a national level.



**96%** **95% TARGET**

of patients referred to a specialist centre were diagnosed within 6 months. And 76% were seen or discharged within 30 days – the best performance since standards began! The target was 50%.



**93%** **95% TARGET**

of patients received a right heart catheterisation before being given drugs to treat PH.

This is an increase of 13% on the previous year!



**92%** **90% TARGET**

of patients who have had at least one consultation in the last year have had an EmPHasis-10 quality of life score recorded.

Here at the PHA UK we championed the introduction of this standard because quality of life is so important



**96%** **95% TARGET**

of patients taking PH medication have had at least one consultation within the last 13 months.

All consultation types, including those not in-person, are included in this standard and statistic



“““

"Despite the challenges that the NHS faces, the National Audit of PH once again demonstrates that the UK provides high quality care for people affected by PH. What makes the audit so unique, and impactful, is the contribution that patients, the PHA UK, healthcare professionals and commissioners have made to ensure that the audit standards reflect what is important to people affected by PH."

Professor David Kiely, Lead Clinician, National Audit of PH



“““

"Our specialist centres are jewels in the crown of the NHS, and as this audit shows, they continue to provide outstanding care. Patients and their loved ones should feel very encouraged by the findings of this report, which provide further assurances of the standards of treatment and support provided by their PH teams."

Dr Iain Armstrong, Chair, PHA UK



The latest National Audit of Pulmonary Hypertension has shown performance against national standards has returned to pre-pandemic levels – with specialist centres continuing to provide a high-quality service to patients.

The National Audit of PH (NAPH) sets out to measure the quality of care provided to people who are referred to pulmonary hypertension services in Great Britain. Data is collected from all the centres in England, and from the Scottish Pulmonary Vascular Unit in Glasgow.



You can view the full National Audit of Pulmonary Hypertension at [www.bit.ly/NationalAuditOfPH](http://www.bit.ly/NationalAuditOfPH)

## Some of the additional findings

STANDARD	RESULT	TARGET
New patients should be seen or discharged within 30 days	<b>76%</b>	50%
Patients should have a vasoreactivity study recorded before treatment (this test helps doctors decide which type of drugs would be most beneficial)	<b>80%</b>	80%
New patients should begin drug therapy within 12 weeks of referral	<b>83%</b>	80%
PH centres should record patient participation in research	<b>29%</b>	20%

The audit is commissioned by NHS England, delivered by NHS Digital, and supported by NHS Scotland, NHS Wales, and the National Pulmonary Hypertension Centres of United Kingdom and Ireland Physicians' Committee.

Here at the PHA UK we also continue to support the audit on behalf of the patient community, after funding its first year. And every year we bring you the key findings in a clear and accessible way, after you told us which of the measures are most important to you.

Created in 2009, the NAPH is the largest audit of pulmonary hypertension in the world and its findings are used to inform future service planning.